Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company offers therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator in development for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. The Company's medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness.

  • Revenue in USD (TTM)92.37bn
  • Net income in USD25.42bn
  • Incorporated1942
  • Employees79.00k
  • Location
    Pfizer Inc235 E 42ND STNEW YORK 10017-5703United StatesUSA
  • Phone+1 (212) 573-2323
  • Fax+1 (302) 655-5049
  • Websitehttps://www.pfizer.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PFE:NYQ since
announced
Transaction
value
Biohaven Pharmaceutical Holding Co LtdAnnounced10 May 202210 May 2022Announced7.55%12.60bn
ReViral LtdDeal completed07 Apr 202207 Apr 2022Deal completed-1.06%525.00m
Arena Pharmaceuticals IncDeal completed13 Dec 202113 Dec 2021Deal completed-0.89%6.68bn
Trillium Therapeutics IncDeal completed23 Aug 202123 Aug 2021Deal completed7.37%2.21bn
Data delayed at least 15 minutes, as of Jul 01 2022 21:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.